ATE206621T1 - Il-8 antagonisten zur behandlung von asthma - Google Patents

Il-8 antagonisten zur behandlung von asthma

Info

Publication number
ATE206621T1
ATE206621T1 AT96921804T AT96921804T ATE206621T1 AT E206621 T1 ATE206621 T1 AT E206621T1 AT 96921804 T AT96921804 T AT 96921804T AT 96921804 T AT96921804 T AT 96921804T AT E206621 T1 ATE206621 T1 AT E206621T1
Authority
AT
Austria
Prior art keywords
asthma
treatment
antagonists
methods
monoclonal antibodies
Prior art date
Application number
AT96921804T
Other languages
English (en)
Inventor
Caroline A Hebert
Rhona C Kabakoff
Mark W Moore
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE206621T1 publication Critical patent/ATE206621T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96921804T 1995-06-27 1996-06-26 Il-8 antagonisten zur behandlung von asthma ATE206621T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/491,334 US5874080A (en) 1994-03-03 1995-06-27 Anti-IL-8 monoclonal antibodies for treatment of asthma
PCT/US1996/011033 WO1997001354A1 (en) 1995-06-27 1996-06-26 Il-8 antagonists for treatment of inflammatory disorders and asthma

Publications (1)

Publication Number Publication Date
ATE206621T1 true ATE206621T1 (de) 2001-10-15

Family

ID=23951745

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96921804T ATE206621T1 (de) 1995-06-27 1996-06-26 Il-8 antagonisten zur behandlung von asthma

Country Status (12)

Country Link
US (1) US5874080A (de)
EP (1) EP0840620B1 (de)
JP (1) JPH11509840A (de)
AT (1) ATE206621T1 (de)
AU (1) AU727343C (de)
CA (1) CA2222024A1 (de)
DE (1) DE69615843T2 (de)
DK (1) DK0840620T3 (de)
ES (1) ES2165506T3 (de)
NZ (1) NZ311561A (de)
PT (1) PT840620E (de)
WO (1) WO1997001354A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100261941B1 (ko) * 1994-07-13 2000-07-15 나가야마 오사무 사람의 인터루킨-8에 대한 재구성 사람항체
IL131406A0 (en) * 1997-02-21 2001-01-28 Genentech Inc Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
US7122636B1 (en) * 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
EP1087661A4 (de) * 1998-06-17 2003-04-16 Smithkline Beecham Corp Il-8 rezeptor antagonisten
US20080038274A1 (en) * 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
US6753135B2 (en) * 2000-09-20 2004-06-22 Surromed, Inc. Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
US20030232048A1 (en) * 2002-03-19 2003-12-18 Xiao-Dong Yang Methods for treating chronic obstructive pulmonary disease (COPD)
US7982008B2 (en) * 2002-11-27 2011-07-19 David Bar-Or Treatment of diseases and conditions mediated by increased phosphorylation
ES2373947T3 (es) * 2002-12-16 2012-02-10 Genmab A/S Anticuerpos monoclonales humanos contra interleucina 8 (il-8).
CA2605964A1 (en) * 2005-04-20 2006-10-26 Amgen Fremont Inc. High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
KR20200108868A (ko) 2018-01-12 2020-09-21 브리스톨-마이어스 스큅 컴퍼니 암을 치료하기 위한 항-il-8 항체 및 항-pd-1 항체와의 조합 요법
WO2023192478A1 (en) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5229275A (en) * 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
PT98072B (pt) * 1990-06-22 1998-11-30 Chiron Corp Processo para a preparacao de polipeptidos contendo proteina macrofagica inflamatoria humana mip-2 alfa por metodos recombinantes e de composicoes farmaceuticas que os contem
US5234911A (en) * 1990-07-09 1993-08-10 Gist-Brocades, N.V. Substance with interleukin-8 inhibiting activity and process for its preparation
IE913192A1 (en) * 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
CA2092924A1 (en) * 1990-09-28 1992-03-29 John Stephen Haskill Gro genes, proteins, and uses thereof
WO1992006697A1 (en) * 1990-10-23 1992-04-30 Repligen Corporation Anti-inflammatory composition
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
JPH0597A (ja) * 1991-06-21 1993-01-08 Snow Brand Milk Prod Co Ltd 新規抗ｔｃｆ−ｉｉモノクローナル抗体及びそれを用いるｔｃｆ−ｉｉの測定方法
WO1993001826A1 (en) * 1991-07-19 1993-02-04 East Carolina University Method of treating asthma
WO1994004173A1 (en) * 1992-08-21 1994-03-03 The Scripps Research Institute Therapeutic compositions and methods for inhibiting il-8-mediated inflammation
WO1995023865A1 (en) * 1994-03-03 1995-09-08 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders

Also Published As

Publication number Publication date
ES2165506T3 (es) 2002-03-16
CA2222024A1 (en) 1997-01-16
DE69615843D1 (de) 2001-11-15
DK0840620T3 (da) 2002-02-04
EP0840620B1 (de) 2001-10-10
US5874080A (en) 1999-02-23
AU727343B2 (en) 2000-12-14
EP0840620A1 (de) 1998-05-13
AU6292496A (en) 1997-01-30
WO1997001354A1 (en) 1997-01-16
PT840620E (pt) 2002-04-29
DE69615843T2 (de) 2002-05-16
AU727343C (en) 2002-01-03
NZ311561A (en) 1999-10-28
JPH11509840A (ja) 1999-08-31

Similar Documents

Publication Publication Date Title
DK0724456T3 (da) CD40-Antistoffer
FI963004L (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
DE69736197D1 (de) Antikoagulierende humanisierte Antikörper gegen Faktor IX, zur Verwendung in der Behandlung von Thrombose
DE69636748D1 (de) Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien
ATE361364T1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DE69116921D1 (de) Verfahren zur Reinigung von monoklonalen Antikörpern
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
ATE348113T1 (de) Rekombinanter anti-cd4 antikörper zur menschlichen behandlung
MX9800760A (es) Metodos para el tratamiento del asma alergica.
DE60033030D1 (de) Verwendung von gegen cd20 gerichteten antikörpern zur behandlung der graft versus host krankheit
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
DE3854502D1 (de) Gegen hiv-antigene spezifischer monoklonaler antikörper.
DE69128273D1 (de) Für toxin b von clostridium difficile spezifische monoklonale antikörper
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
DK0812206T3 (da) Fremgangsmåde til stimulering af en immunrespons
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
EA199700196A1 (ru) Способ получения фактора ix из биологических источников и фактор ix, полученный этим способом
DE3485712D1 (de) Monoklonale antikoerper gegen menschliche nierenkrebsantigene und verfahren.
DE3580482D1 (de) Monoklonale antikoerper und immunisierung damit.
ATE309371T1 (de) Protein mit dnase-aktivität

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee